%0 Journal Article
%T A new alternative: inhibiting complement activation in patients with IgA nephropathy.
%A Floege J
%J Kidney Int
%V 105
%N 1
%D 2024 01
%M 38182298
%F 18.998
%R 10.1016/j.kint.2023.10.012
%X Mesangial complement C3 deposits, reflecting alternative and possibly lectin pathway activation, are characteristic in biopsies of patients with IgA nephropathy (IgAN). A recent randomized controlled trial tested the efficacy and safety of iptacopan, a factor B inhibitor, in patients with IgAN. Iptacopan dose-dependently reduced proteinuria, and there was a pronounced decrease of urinary C5b-9. This offers the perspective of "personalizing" therapy, which would be a unique feature of this novel approach to IgAN. A phase III clinical trial (APPLAUSE-IgAN) is ongoing.